Prednisolone

Prednisolone (50 mg/kg, im) given 15 min before LPS-attenuated production of NO2- and NO3- by neutrophils and suppresses LPS-stimulated mRNA for NOS II in rat neutrophils. ^[1] Prednisolone reduces joint swelling through a mechanism associated with a reduction in IL-1beta and IL-6 protein and mRNA expression levels in SCW-induced arthritis rats. ^[2] Prednisolone's anti-inflammatory effects can be mediated by reducing cellular adhesion molecule (CAM) expression. Prednisolone (0.75 mg/kg) reduces macrophages (-59%, -57%), CD4(+) T-cells (-50%, -60%), CD8(+) T-cells (-58%, -48%), and eosinophils (-36%, -25%) in quadriceps and soleus muscles, respectively. Prednisolone-treated mice also exhibits decreased vascular P-selectin (-82%) and ICAM-1 (-52%) expression and fewer L-selectin (-79%) and ICAM-1 (-57%) expressing mononuclear cells in quadriceps. Prednisolone reduces sarcolemmal damage and degeneration as well in Dystrophin-deficient, mdx mice. ^[3]

Prednisolone (5 mg/kg) causes alterations in diaphragmatic contractile properties and histological changes without fiber atrophy in rats. Prednisolone results in an increased number of diaphragmatic bundles in rats. ^[4] Prednisolone induces a significant decline of PL-pO2, while CoBF, CMs, CAPs, and ABRs revealed no change in guinea pigs. ^[5]